Wells Fargo analyst Derek Archila is reiterating an Overweight rating after Prometheus reported positive results for its Phase 2 studies in ulcerative colitis and Crohn’s disease. The analyst thinks shares should be up meaningfully on the results, at least a double from current levels given this is in line with his bull case. Archila thinks it is clear that Prometheus has a UC drug on its hands for all-comers and is highly active.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RXDX:
- Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
- Prometheus Biosciences Shares Tripled Today after Positive Drug Results
- Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
- Prometheus Biosciences put volume heavy and directionally bearish
- Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress